Biomerica announces inFoods IBS pilot launch

Biomerica announced the initiation of a pilot program for its inFoods IBS product with a large 1,100-member physician group. This pilot launch will commence in June 2024. inFoods IBS offers a novel approach by identifying individual patient specific dietary triggers for IBS symptoms, which could revolutionize management of the condition. This technology has demonstrated remarkable success in alleviating symptoms for the majority of patients participating in the most extensive clinical study of its kind. The inFoods IBS product has undergone rigorous testing in a prospective, double-blind, placebo-controlled endpoint study conducted at prestigious institutions including the Mayo Clinic, Beth Israel Deaconess Medical Center, Houston Methodist Hospital, and the University of Michigan. The study results revealed a significant improvement in Abdominal Pain Intensity scores for IBS patients in the treatment diet arm compared to those in the placebo diet arm. Notably, this study found that the majority of IBS patients experienced remarkable relief with inFoods IBS.